Paclitaxel combined with oxaliplatin as first-line chemotherapy for locally advanced or metastatic gastric cancer

References

• Chen W, Zheng R, Zhang S, et al. Report of cancer incidence and mortality in China, 2010. Ann Transl Med 2014;2(7):61
   PubMedGoogle Scholar
• Florian L, Sylvie L, Yasuhide Y, et al. Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer 2014;17(2):213-25
   PubMedGoogle Scholar
• Ichikawa W, Sasaki Y. Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients. Ann Oncol 2006;17(11):1665-72
   PubMed Web of Science ®Google Scholar
• Shitara K, Matsuo K, Muro K, et al. Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy. J Cancer Res Clin Oncol 2013;139(8):1383-839
   PubMedGoogle Scholar
• Hashimoto K, Takashima A, Nagashima K, et al. Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer. J Cancer Res Clin Oncol 2010;136(7):1059-64
   PubMedGoogle Scholar
• Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010;17(3):CD004064
   Google Scholar
• Yoshida K, Fujii M, Koizumi W, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006;12(11 Pt 1):3402-7
   PubMedGoogle Scholar
• Wasaburo K, Yeul HK, Masashi F, et al. The JACCRO and KCSG Study Group. Addition of docetaxel to S1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol 2014;140(2):319-28
   PubMedGoogle Scholar
• Park SH, Lee WK, Chung M, et al. Paclitaxel versus docetaxel for advanced gastric cancer: a randomized Phase II trial in combination with infusional 5-fluorouracil. Anticancer Drugs 2006;17:225-9
   PubMed Web of Science ®Google Scholar
• Chon HJ, Rha SY, Im CK, et al. Docetaxel versus paclitaxel combined with 5 FU and leucovorin in advanced gastric cancer: combined analysis of two Phase II trials. Cancer Res Treat 2009;41:196-204
   PubMedGoogle Scholar
• Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358(18):36-46
   PubMedGoogle Scholar
• Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26(9):1435-42
   PubMed Web of Science ®Google Scholar
• Koizumi W, Takiuchi H, Yamada Y, et al. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol 2010;21(5):1001-5
   PubMedGoogle Scholar
• Kim GM, Jeung HC, Rha SY, et al. A randomized Phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer 2012;48(4):518-26
   PubMed Web of Science ®Google Scholar
• Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised Phase III non inferiority trial. Ann Oncol 2009;20:666-73
   PubMed Web of Science ®Google Scholar
• Bouché O, Raoul JL, Bonnetain F, et al. Randomized multicenter Phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study – FFCD 9803. J Clin Oncol 2004;22(21):4319-28
   PubMed Web of Science ®Google Scholar
• Dank M, Zaluski J, Barone C, et al. Randomized Phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008;19(8):1450-7
   PubMed Web of Science ®Google Scholar
• Sym SJ, Hong J, Park J, et al. A randomized Phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. Cancer Chemother Pharmacol 2013;71(2):481-8
   PubMed Web of Science ®Google Scholar
• Ilson DH, Forastiere A, Arquette M, et al. A Phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000;6(5):316-23
   PubMed Web of Science ®Google Scholar
• Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005;23(24):5660-7
   PubMedGoogle Scholar
• Burtness B, Gibson M, Egleston B, et al. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol 2009;20(7):1242-8
   PubMed Web of Science ®Google Scholar
• Rongbo L, Nanfeng F, Zengqing G, et al. A Phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as first-line treatment for patients with advanced gastric cancer. J Chemother 2008;20(6):744-8
   PubMedGoogle Scholar
• Guo Z, Wang X, Lin R, et al. Paclitaxel-based regimens as first-line treatment in advanced gastric cancer. J Chemother 2015;27(2):94-8
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, et al. Capecitabine and Oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46
   PubMed Web of Science ®Google Scholar
• Lee JL, Kang YK, Kang HJ, et al. Randomised multicentre Phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 2008;99(4):584-90
   PubMed Web of Science ®Google Scholar
• Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 2013;63(6):419-37
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase III, open-label, randomised controlled trial. Lancet 2010;376(9742):687-97
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, Phase III trial. Lancet 2014;383(9911):31-9
   PubMed Web of Science ®Google Scholar
• Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised Phase III trial. Lancet Oncol 2014;15(11):1224-35
   PubMed Web of Science ®Google Scholar